NASDAQ: ATOSAtossa Therapeutics Inc Stock
$1.42+0.07 (+5.19%)
Updated Apr 18, 2024
ATOS Price
$1.42
Fair Value Price
$0.70
Market Cap
$177.93M
52 Week Low
$0.59
52 Week High
$2.31
P/E
-5.92x
P/B
1.95x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$21M
Beta
1.14
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ATOS Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATOS ($1.42) is overvalued by 102.14% relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ATOS ($1.42) is not significantly undervalued (102.14%) relative to our estimate of its Fair Value price of $0.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATOS due diligence checks available for Premium users.
Be the first to know about important ATOS news, forecast changes, insider trades & much more!
ATOS News
Valuation
ATOS fair value
Fair Value of ATOS stock based on Discounted Cash Flow (DCF)
Price
$1.42
Fair Value
$0.70
Overvalued by
102.14%
ATOS ($1.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATOS ($1.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATOS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.92x
Industry
15.68x
Market
41.33x
ATOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.95x
Industry
5.76x
ATOS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATOS's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.8M
Profit Margin
0%
ATOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$96.3M
Liabilities
$5.2M
Debt to equity
0.06
ATOS's short-term assets ($92.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATOS's short-term assets ($92.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATOS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.6M
Investing
$0.0
Financing
$0.0
ATOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATOS vs Biotech Stocks
Atossa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.